{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053931","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.543520+00:00","generated_at":"2026-06-02T18:58:16.962510+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prelude Therapeutics Q1 net loss $31.4M; cash $201.9M; pipeline on track for H2 2024 data","bullets":["Net loss $31.4M ($0.42/diluted share) vs $27.7M ($0.58) in Q1 2023; R&D spend $27.4M up from $21.8M.","Cash, equivalents & marketable securities $201.9M as of March 31, 2024; cash runway expected into 2026.","PRT3789 (SMARCA2 degrader) and PRT2527 (CDK9 inhibitor) on track for initial proof-of-concept data H2 2024.","PRT7732 oral SMARCA2 degrader expected to enter Phase 1 in H2 2024; IND-enabling studies ongoing.","Appointed Sean Brusky as CBO and Robert Doody as SVP, IR in April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053931","json":"https://secwatch.observer/filing/0000950170-24-053931.json","markdown":"https://secwatch.observer/filing/0000950170-24-053931.md","text":"https://secwatch.observer/filing/0000950170-24-053931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024053931/0000950170-24-053931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024053931/prld-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:58:16.962510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56d910ab0efd850d52d850f9b773327eabe3bc38","claim":"Prelude Therapeutics Inc reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 7, 2024, Prelude Therapeutics Incorporated (the \"Company\") issued a press release announcing its financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024053931/0000950170-24-053931-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}